British Journal of Cancer
This journal is devoted to publishing cutting edge discovery, translational and clinical cancer research across the broad spectrum of oncology.
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer
In this clinical study, we have validated a 44 gene expression based DDIR signature as a predictor of response to neoadjuvant chemotherapy in breast cancer, which can be integrated into clinical workflows, and potentially identifies a subgroup of cancers responsive to anthracycline treatment.
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It’s increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). However, little is known on PPI effects on outcomes with ICIs.
Higher Bleeding Rates Found with Direct Oral Anticoagulants in Myeloproliferative Neoplasm Patients
In this study we evaluated thrombosis and bleeding outcomes in myeloproliferative neoplasm (MPN) patients treated with direct oral anticoagulants (DOACs). We found an unexpected high cumulative incidence of bleeding, emphasizing the need for continued rigorous evaluation of DOACs in MPNs.
